1. Non-invasive evaluation of botulinum-A toxin treatment efficacy in children with refractory overactive bladder
- Author
-
Murat Uçar, Ahsen Karagözlü Akgül, Emin Balkan, Cem Yücel, Ayse Parlak, and Nizamettin Kılıç
- Subjects
Male ,Nephrology ,medicine.medical_specialty ,Time Factors ,Adolescent ,Urology ,Dysfunctional voiding ,030232 urology & nephrology ,Urination ,Urinary incontinence ,03 medical and health sciences ,0302 clinical medicine ,Refractory ,Internal medicine ,medicine ,Humans ,Botulinum Toxins, Type A ,Child ,Retrospective Studies ,Botulinum a toxin ,Dose-Response Relationship, Drug ,Urinary Bladder, Overactive ,business.industry ,Non invasive ,medicine.disease ,Treatment efficacy ,Administration, Intravesical ,Treatment Outcome ,Neuromuscular Agents ,Overactive bladder ,030220 oncology & carcinogenesis ,Female ,medicine.symptom ,business ,Follow-Up Studies - Abstract
We aimed to evaluate the efficacy and safety of intravesical onabotulinum toxin A (onaBoNTA) injections for the treatment of children diagnosed with refractory overactive bladder (OAB) by using non-invasive methods. A total of 31 pediatric patients with a mean age of 10.2 years received intravesical onaBoNTA injection at the dose of 10 U/kg (max: 200 U). Twenty-one patients who failed to respond to the first injection, received second injection 6 months after the first one. The patients were retrospectively evaluated after the 1st and the 2nd injections by means of standardized questionnaire forms and voiding diary records. In the 6-month follow-up, 10 patients (32.2%) were determined to have full response after the first injection. The number of patients with partial response and no response were found to be 15 (48.4%) and 6 (19.4%), respectively. The mean value of Dysfunctional Voiding and Incontinence Symptom Score (DVISS) of the patients with full response was 8.5 before the injection, which decreased to 1 at 6-month follow-up and to 0.5 at 12-month follow-up (p
- Published
- 2018
- Full Text
- View/download PDF